Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis

Novel Bispecific Antibody for Synovial-Specific Target Delivery of Anti-TNF Therapy in Rheumatoid Arthritis

Biologic drugs, especially anti-TNF, are considered as the gold standard therapy in rheumatoid arthritis. However, non-uniform efficacy, incidence of infections, and high costs are major concerns. Novel tissue-specific agents may overcome the current limitations of systemic administration, providing...

Full description

Bibliographic Details
Main Authors: Mathieu Ferrari, Shimobi C. Onuoha, Liliane Fossati-Jimack, Alessandra Nerviani, Pedro L. Alves, Sara Pagani, Cecilia Deantonio, Federico Colombo, Claudio Santoro, Daniele Sblattero, Costantino Pitzalis
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Immunology
Subjects:
rheumatoid arthritis
anti-TNF therapy
bispecific antibody
targeted therapy
biological drugs
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2021.640070/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2021.640070/full

Similar Items